Baleigh Ford, PA
Medical · Vicksburg, MSNPI 1114387123
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 112 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 16.9% — the pattern of someone who eats at a lot of different presentations.
Across 112 payments — averaging $17.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$327
- Mylan Specialty L.p.$238
- AbbVie$225
- Amgen$159
- Astellas Pharma US Inc$116
- Abbott$107
- plus $766 from 20 others
What the payments were for
- Food & beverage$1,92499%
- Education$141%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 17 | $327 |
| Mylan Specialty L.p. | 12 | $238 |
| AbbVie | 13 | $225 |
| Amgen(2 entities) | 11 | $159 |
| Astellas Pharma US Inc | 5 | $116 |
| Abbott | 7 | $107 |
| Novartis | 5 | $84 |
| Novo Nordisk | 6 | $80 |
| GSK | 5 | $77 |
| Merck | 4 | $67 |
| Otsuka America Pharmaceutical, Inc. | 4 | $61 |
| Lundbeck LLC | 3 | $60 |
| Lilly USA, LLC | 4 | $55 |
| Boehringer Ingelheim | 3 | $50 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $30 |
| Phathom Pharmaceuticals, Inc. | 1 | $25 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| Lexicon Pharmaceuticals, Inc. | 1 | $22 |
| Sunovion Pharmaceuticals Inc. | 1 | $22 |
| Jazz Pharmaceuticals Inc. | 1 | $20 |
| Alnylam Pharmaceuticals Inc. | 1 | $17 |
| Ironwood Pharmaceuticals, Inc | 1 | $16 |
| Bayer | 1 | $15 |
| Daiichi Sankyo Inc. | 1 | $15 |
| Exact Sciences | 1 | $14 |
| Cumberland Pharmaceuticals, Inc. | 1 | $13 |
How this compares
$1,938 in reported general payments places this provider in the 55th percentile of 65 medical providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KrystexxaPegloticase | 18 | $538,744 |
| MounjaroTirzepatide | 97 | $119,992 |
| JardianceEmpagliflozin | 106 | $91,649 |
| OzempicSemaglutide | 77 | $82,019 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 66 | $72,221 |
| JanuviaSitagliptin Phosphate | 81 | $66,022 |
| XareltoRivaroxaban | 71 | $51,318 |
| EliquisApixaban | 68 | $44,990 |
| LinzessLinaclotide | 42 | $35,248 |
| FarxigaDapagliflozin Propanediol | 39 | $31,493 |
| TrulicityDulaglutide | 21 | $27,111 |
| RexultiBrexpiprazole | 11 | $18,458 |
| MyrbetriqMirabegron | 20 | $13,045 |
| Potassium Chloride | 457 | $8,252 |
| Novolog FlexpenInsulin Aspart | 30 | $5,479 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenKrystexxa | $159 | $538,74418 claims |
| Lilly USA, LLCMounjaro, Trulicity | $55 | $147,103118 claims |
| Boehringer IngelheimJardiance | $50 | $91,649106 claims |
| Novo NordiskOzempic | $80 | $82,01977 claims |
| GSKTrelegy Ellipta | $77 | $72,22166 claims |
| MerckJanuvia | $67 | $66,02281 claims |
| AbbVieLinzess, Synthroid | $225 | $38,47196 claims |
| AstraZenecaFarxiga, Symbicort | $327 | $36,54953 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $61 | $18,45811 claims |
| Astellas Pharma US IncMyrbetriq | $116 | $13,04520 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 65 medical providers in Mississippi.
Other medical in Vicksburg
- Heather AndersonVicksburg$2K
- Patricia LewisVicksburg$659
- Shannon YoungerColumbus$63K
- Angela DauroBiloxi$25K
- Jenna HabermanFlowood$14K
- Ashley LarsenOcean Springs$11K
- Elise BuckleyClinton$10K
- Caroline BaldwynMadison$9K
- Miranda SudduthMadison$8K
- Catherine DiazFlowood$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.